Fingerpaint Group Acquires The MYND Group
Deal is expected to boost company’s market access capabilities.
Fingerpaint Group, an integrated collective of healthcare companies that provide commercialization solutions that span the entire product life cycle, is strengthening its market access offering with the acquisition of The MYND Group, a full-service strategic market access marketing company that works in the pharma and biologics spaces.
The company joins Fingerpaint Group's specialty services offerings that include medical and scientific communications, market access, and naming and branding capabilities.
"The MYND Group brings extensive market access strategy, research, and launch experience across multiple categories, including in the growing vaccine category," notes Bill McEllen, Fingerpaint Group’s global president. "This is our second market access acquisition in the last 3 years and is part of our continued commitment to evolving our market access capabilities to match the expectations and needs of the industry."
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
